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supplemented with T cell receptor (TCR) signalingmotifs func-
tion as activation receptors and can redirect gene-modiﬁed
T cells against pathogenic CD8 T cells. We have shown that
b2 microglobulin (b2m) operates as a universal signaling
component of MHC-I molecules when fused with the CD3-z
chain. Linking theH-2Kd-binding insulin B chain peptide insu-
lin B chain, amino acids 15–23 (InsB15–23) to the N terminus of
b2m/CD3-z, redirected polyclonal CD8 T cells against patho-
genic CD8 T cells in a peptide-speciﬁc manner in the non-obese
diabetic (NOD) mouse. Here, we describe mRNA electropora-
tion for delivering peptide/b2m/CD3-z genes to a reporter
T cell line and puriﬁed primary mouse CD8 T cells. The pep-
tide/b2m/CD3-z products paired with endogenous MHC-I
chains and transmitted strong activation signals upon MHC-I
cross-linking. The reporter T cell line transfected with
InsB15–23/b2m/CD3-z mRNA was activated by an InsB15–23-
H-2Kd-speciﬁc CD8 T cell hybrid only when the transfected
T cells expressed H-2Kd. Primary NOD CD8 T cells expressing
either InsB15–23/b2m/CD3-z or islet-speciﬁc glucose-6-
phosphatase catalytic subunit-related protein, amino acids
206–214 (IGRP206–214)/b2m/CD3-z killed their respective au-
toreactive CD8 T cell targets in vitro. Furthermore, transfer
of primary CD8 T cells transfected with InsB15–23/b2m/CD3-
z mRNA signiﬁcantly reduced insulitis and protected NOD
mice from diabetes. Our results demonstrate that mRNA en-
coding chimeric MHC-I receptors can redirect effector CD8
against diabetogenic CD8 T cells, offering a new approach
for the treatment of type 1 diabetes.Received 15 July 2016; accepted 5 December 2016;
http://dx.doi.org/10.1016/j.ymthe.2016.12.007.
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Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in
which both CD4 and CD8 T cells (CTLs) target insulin-producing
islet b cells. In human T1D, islet-speciﬁc CTLs have been identiﬁed
and histology shows CTLs in the islets, whereas in the non-obese dia-
betic (NOD)mouse, CTLs are implicated in the initial stages as well as
in progression of disease.1–6 Selective immunotargeting of diabeto-456 Molecular Therapy Vol. 25 No 2 February 2017 ª 2016 The Americangenic CTLs is therefore a promising avenue for immunotherapy
of T1D.
The CD3-z chain is an essential signaling component of the T cell
receptor (TCR) complex. T cells genetically redirected through
major histocompatibility complex (MHC)-I heavy (a) chains fused
with CD3-z and supplemented with a peptide of choice can target
peptide-speciﬁc CD8 T cells, initially achieved through the expres-
sion of MHC-Ia/CD3-z fusion proteins. For example, T cells ex-
pressing chimeric H-2Kb/CD3-z and pulsed with a distinct peptide
exhibited efﬁcient cytolysis of antigen-speciﬁc cytotoxic CTL pre-
cursors.7 Furthermore, transgenic T cells of a unique memory
phenotype expressing an H-2Dd/CD3-z construct potently vetoed
responses to H-2Dd in vitro.8 The addition of a cognate H-2Dd pep-
tide endowed these transgenic cells with cytolytic activity against an
antigen-speciﬁc T cell hybridoma. The polymorphic MHC-I heavy
chain is non-covalently associated with an invariant, non-MHC-en-
coded b2 microglobulin (b2m) light chain, not anchored to the
plasma membrane. We have shown that b2m can serve as a versatile
molecular scaffold for chimeric MHC-I/CD3-z T cell activation re-
ceptors.9 A single b2m/CD3-z-based expression cassette enables co-
valent linking of any pre-selected peptide to the N terminus of b2m,
so as to redirect T cells at autoreactive CD8 T cells of a given
speciﬁcity.
A number of cloned diabetogenic CTLs from the NOD mouse target
identiﬁed antigens. Proinsulin is a major target antigen for diabeto-
genic CTLs, both in the NOD mouse10 and in humans.11–17 G9C8 is
a highly pathogenic CTL clone that recognizes insulin B chain,
amino acids 15–23 (InsB15–23) in the context of H-2K
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the early CD8 T cell inﬁltrate detected as early as 4 weeks of
age.10,19 Later, CD8 T cells reactive against an H-2Kd-binding
peptide from islet-speciﬁc glucose-6-phosphatase catalytic subunit-
related protein, amino acids 206–214 (IGRP206–214)
20–23 become
dominant. A third islet-reactive, pathogenic NOD CTL, although
initially thought to be speciﬁc to a dystrophia myotonica kinase,
amino acids 138–146 (DMK138–146) peptide, is actually reactive to
insulin.23–25 Interestingly, the relative distribution in the inﬁltrate
of T cells varies considerably among individual mice, deﬁning a
unique immunological signature.20–23 CD8 T cells reactive to gluta-
mic acid decarboxylase (GAD65)—especially GAD65, amino acids
546–554 (GAD65546–554)—have also been identiﬁed in the NOD
mouse.26,27
Immune responses to proinsulin are necessary for IGRP-reactive
CTLs to expand28,29 and to cause diabetes. Therefore, early immuno-
logical intervention selectively targeting dominant CTL clones may
arrest b cell destruction and inhibit, or entirely prevent, the onset
of disease. As a proof of concept, we previously generated NOD
mice expressing an InsB15–23/b2m/CD3-z construct in CD8
T cells.30 CTLs from these mice killed InsB15–23-reactive target CD8
T cells and protected NOD SCID (severe combined immunodeﬁ-
ciency) mice from diabetes when co-transferred with the pathogenic
T cells and signiﬁcantly reduced spontaneous diabetes in wild-type
NOD mice.31
Transfection of mRNA to modify primary human and mouse
T cells has drawn considerable interest. Electroporation of
mRNA is fast, simple, and exceptionally efﬁcient and drives high
and uniform expression under mild conditions, thereby preserving
cell viability. Although transient, mRNA transfection can drive
functional expression of the introduced genes up to 5–7 days
and more.32–36 The use of mRNA entirely obviates the risk of
cellular transformation and allows the co-introduction of several
genes as pre-deﬁned mixtures, which is often limited with other
gene delivery vehicles.
Here we show that CD8 T cells can be reprogrammed to recognize
diabetogenic T cells following the electroporation of mRNA encoding
peptide/b2m/CD3-z and this can target autoreactive CTLs in vivo to
reduce insulitis and prevent autoimmune diabetes in the NOD
mouse.
RESULTS
Assembly and Expression of Peptide/b2m/CD3-z Constructs in
Reporter T Cells
We ﬁrst assembled four DNA templates for in vitro transcription of
mRNA encoding peptide/b2m/CD3-z, incorporating InsB15–23,
IGRP206–214, DMK138–146, or GAD65546–554. Figures 1A and 1B,
respectively, illustrate the genetic design and the anticipated
MHC-I complexes comprising the chimeric polypeptide chains. Hu-
man b2m (hb2m), which was used throughout this study, has been
shown to associate efﬁciently with mouse MHC-I heavy chains37–39and is useful for detecting expression of the resulting MHC-I com-
plexes. Flow cytometric analysis conﬁrmed the expression of hb2m
at the cell surface of CD8 T cells puriﬁed from BALB/c and NOD
mice and the reporter B3Z T cell hybridoma following mRNA
transfection (Figure 1C). This expression was reproducible over
many experiments. We then evaluated the effect of the amount of
InsB15–23/b2m/CD3-z mRNA used for electroporation and level of
expression in B3Z cells. Indeed, both ﬂow cytometry and western
blot analyses for hb2m (Figures 1D and 1E) revealed dose-depen-
dent expression, which was not accompanied by a reduction in
cell viability at the higher mRNA concentrations (not shown).
Western blot analysis, which was performed under reduced condi-
tions, revealed a band of approximately 33 kDa, in accordance
with the calculated molecular weight of the InsB15–23/b2m/CD3-z
polypeptide product.
Function of Peptide/b2m/CD3-z Constructs in Reporter T Cells
We tested whether the new MHC-I complexes expressed at the cell
surface can indeed function as T cell activation receptors. To this
end, we transfected B3Z reporter cells with mRNA encoding each
of four peptide/b2m/CD3-z polypeptides, with or without mRNA
encoding the full-length H-2Kd heavy chain. The B3Z cells endoge-
nously express the MHC-I H-2Db, but not the H-2Kd necessary for
antigen presentation of some of the transfected peptides in the NOD
mouse, necessitating the transfection of the appropriate MHC-I
complex in addition to the peptide/b2m/CD3-z. The four peptides
were derived from previously identiﬁed autoantigens in diabetes
in the NOD mouse, which express the MHC-I H-2Kd and H-2Db.
These were insulin B chain, amino acids 15–23 (InsB15–23), islet-spe-
ciﬁc glucose-6-phosphatase catalytic subunit-related protein, amino
acids 206–214 (IGRP206–214), and glutamic acid decarboxylase,
amino acids 546–554 (GAD65546–554), which are presented by
MHC-I H-2Kd. Dystrophia myotonica kinase, amino acids
138–146 (DMK138–146), binds H-2D
b, which is naturally expressed
by B3Z cells. Transfected cells were then incubated in the presence
or absence of immobilized antibodies against the respective MHC-I
heavy chain and T cell activation was monitored by a reporter assay
(Figure 2A). Clearly, this experiment indicates that the polypeptide
products functionally paired with exogenous (H-2Kd) or endoge-
nous (H-2Db) heavy chains at the plasma membrane and, when
triggered by the anti-MHC-I antibody binding and hence cross-
linking MHC-I, potent activation signals were transmitted. These
signals were comparable in magnitude to those produced by simi-
larly cross-linking the endogenous TCR expressed by B3Z cells as
shown by the response seen with anti-CD3 antibody 2C11. We
then assessed the ability of InsB15–23b2m/CD3-z expressed by B3Z
to mediate peptide-speciﬁc T cell activation in target T cells express-
ing an anti-InsB15–23-H-2K
d TCR. To this end, we used the CHIB2
T cell hybridoma, which expresses the abTCR of the diabetogenic
G9C8 CD8 T cell clone that recognizes the insulin B chain peptide,
amino acids 15–23. We observed construct-mediated recognition
upon co-culture of the two cells (Figure 2B) only when B3Z
expressed both InsB15–23/b2m/CD3-z and H-2K
d. As both cells
express the same nuclear factor of activated T cells (NFAT)-lacZMolecular Therapy Vol. 25 No 2 February 2017 457
Figure 1. Gene, Product and Expression of Peptide/b2m/CD3-z
(A) Genetic design. Selected restriction sites are shown. br, bridge; lead, leader peptide; li, linker; p, peptide; pr, promoter; tm+cyt, transmembrane and cytoplasmic domain.
(B) Scheme of an intact, surface MHC-I complex comprising the chimeric peptide/b2m/CD3-z chain. (C) Flow cytometric analysis for surface expression. Splenic CD8 T cells
of BALB/c and NOD mice (upper panel) and B3Z cells (lower panel) were transfected with 10 mg mRNA encoding the indicated constructs. mRNA encoding H-2Kd was
added to enable presentation of the respective peptides. Cells were stained with anti-human b2m and detected with FITC-conjugated donkey anti-mouse IgG. Staining of
non-transfected cells is presented by the gray histograms. (D) Flow cytometric analysis of B3Z cells electroporated with different amounts of mRNA (in micrograms), no
mRNA, or EGFP mRNA and analyzed using anti-human b2m mAb purified from the supernatant of hybridoma HB149. (E) Western blot analysis performed under reduced
conditions with cell lysates of B3Z cells transfected with the same mRNA as in (D), with detection using rabbit anti-human b2m polyclonal antibodies (Abs).
Molecular Therapyreporter gene, this assay does not discriminate between the two.
However, it coincides with our previous work31 showing two-way
T cell activation mediated by the G9C8 TCR and the InsB15–23/
b2m/CD3-z construct, as the G9TCR recognizes the construct and
the triggering of the construct activates the transfected cell. Here
we recapitulate this notion also for exogenous mRNA-driven
expression.458 Molecular Therapy Vol. 25 No 2 February 2017Functional Expression of Peptide/b2m/CD3-z in NOD CD8 T
Cells
We went on to test whether polyclonal NOD CD8 T cells can be en-
dowed with the ability to kill diabetogenic T cells following electropo-
ration with peptide/b2m/CD3-zmRNA. In the experiment presented
in Figure 3A, we employed CHIB2 T cell hybridomas as target cells.
Polyclonal CD8 T cells transfected to express InsB15–23/b2m/CD3-z
Figure 2. CD8 T Cell-Targeting Genes Are Functionally Expressed in a
Reporter T Cell Hybridoma following mRNA Transfection
(A) B3Z hybridoma cells, endogenously expressing MHC H-2Db, were used as re-
porter T cell hybridomas expressing the immunotherapeutic targeting constructs
that encompassed peptides from four autoantigens important in diabetes: GAD,
DMK, IGRP, and insulin. GAD, IGRP, and insulin peptides require presentation by
MHCH-2Kd, which is not endogenously expressed by B3Z cells. Thus, the B3Z cells
were transfected with 10 mg of each of the indicated mRNAs with or without H-2Kd
mRNA. The peptide from DMK is presented by H-2Db, endogenously expressed by
the B3Z. The peptide/b2m/CD3-z polypeptides pair with exogenous H-2K
d (GAD,
IGRP, and insulin) or endogenous H-2Db (DMK) heavy chains and transmit T cell
activation signals upon MHC-I cross-linking by plate-bound anti-Kd or anti-Db. The
assay was performed by incubating the transfected cells overnight in 96-well plates
coated with anti-Kd or anti-Db. Cell lysates were prepared and subjected to a CPRG
colorimetric assay. When these indicator T cells expressing the targeting construct
were triggered, either by binding to an anti-Kd or anti-Db antibody, a color change
was seen in the lysates. The negative controls were cells with transfected construct,
but no stimulation with anti-Kd or anti-Db antibody, or in the case of GAD, IGRP, and
insulin peptides, no exogenous MHC construct. The positive control is shown as
B3Z stimulated by anti-CD3 antibody, 2C11, indicating that when the B3Z cells are
triggered through their own endogenous TCR, they are able to effect the color
change, which is a positive control for the cell activation. (B) The B3Z cells were
transfected with the InsB15–23 peptide construct with or without H-2K
d. The cells
were co-incubated overnight in triplicate in a 96-well plate, the cells were lysed, and
the lysate was analyzed by the CPRG colorimetric assay. The B3Z cells transfected
www.moleculartherapy.org(effectors) were incubated with CHIB2 (targets) at three different
effector-to-target (E:T) ratios and dose-dependent killing of the target
CHIB2 cells was observed. We previously showed that expression of
the peptide/b2m/anchor conﬁguration resulted in exceptionally high
occupancy of the restricting MHC-I product by the linked peptide.9,40
To supplement the endogenous H-2Kd in the polyclonal NOD CD8
T cells, we tested the addition of mRNA encoding H-2Kd heavy
chains. Figure 3A illustrates that the transfected polyclonal CD8
T cells have acquired the ability to kill the target CHIB2 cells and
overexpression of H-2Kd had no discernible effect on the killing activ-
ity. Example ﬂow cytometric plots are shown in Figure S1. Figure 3B
presents the results of a similar cell cytotoxicity assay, showing that
NOD CD8 T cells transfected with InsB15–23/b2m/CD3-z or
IGRP206–214/b2m/CD3-z mRNA, respectively, kill target T cells ex-
pressing insulin-reactive G9C8 or IGRP-reactive NY8.3 TCRs puri-
ﬁed from the corresponding TCR transgenic NOD mice. Example
ﬂow cytometric plots from Figure 3 are shown in Figure S1.
CD8 T Cells Redirected to Kill Insulin-Reactive CD8 T Cells
Reduce Diabetes
Having shown that the redirected CD8 T cells were able to kill insulin-
reactive or IRGP-reactive T cells in vitro, we then tested the effect of
the redirected CD8 T cells on the incidence of diabetes in vivo. CD8
T cells transfected with either InsB15–23/b2m/CD3-z or IGRP206–214/
b2m/CD3-zmRNA were adoptively transferred into 5- to 6-week-old
female NOD mice in a single transfer. These mice were tested weekly
for glycosuria and diabetes was conﬁrmed by a blood glucose reading
of >13.9 mmol/L. The mice were euthanized either when they became
diabetic or at 35 weeks if they were non-diabetic. We observed a sig-
niﬁcant reduction in the incidence of diabetes when the cells were
transfected with the InsB15–23/b2m/CD3-z mRNA construct but not
with the IGRP206–214/b2m/CD3-zmRNA construct, as shown in Fig-
ure 4A. Furthermore, there was a clear reduction in insulitis, the inﬁl-
tration of lymphocytes, in the non-diabetic mice, compared with the
insulitis in diabetic mice, with signiﬁcant differences in composition
of the inﬁltration of CD4 and CD8 T cells as well as B cells (Figures 4B
and 4C).
DISCUSSION
In this study, we have shown that mRNA constructs encoding auto-
antigenic peptide/b2m/CD3-z can be used to transfect both T cell
hybrids as well as polyclonal T cells and redirect these T cells against
autoreactive pathogenic CTLs. This means of selectively targeting an-
tigen-speciﬁc cells is a modiﬁcation of the successful chimeric antigen
receptor (CAR) strategy adopted for tumor adoptive cell therapy41
and could be used in adoptive cell therapy in type 1 diabetes.
There is good expression of the constructs and we have shown that
functionally, the redirected targeting cells are recognized speciﬁcallywith the InsB15–23 peptide construct together with H-2K
d can be recognized by
the CHIB2 cells and this recognition stimulates activation of the B3Z cells, indicated
by the color change. The error bars represent SD of the mean from triplicate
experiments.
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Figure 3. Peptide/b2m/CD3-zmRNA Redirects NOD CD8 T Cells to Kill Insulin Reactive CHIB2 T-Hybridoma Cells and Insulin Peptide-Specific CD8 T Cells
(A) Effector cells transfected with InsB15–23/b2m/CD3-z mRNA (NOD Ins; shown in gray filled bars) or InsB15–23/b2m/CD3-z mRNA together with additional H-2K
d [NOD
(Kd+Ins)]; shown in the black filled bars) were co-incubated for 24 hr with PKH26-labeled target CHIB2 cells at effector target ratios of 10:1, 20:1, and 40:1. TO-PRO-3 was
added to the cells and the percentage of lysed target CHIB2 cells was determined by flow cytometric analysis. As controls (shown in the top three bars), target CHIB2 cells
alone (white open bars), effector cells electroporated in the absence ofmRNA (NOD noRNA; light hatched bars), or effector cells electroporated withmRNA encoding only the
MHC (NOD Kd) but not the peptide (dark hatched bars) were each incubated with target cells. (B) Effector cells transfected with InsB15–23/b2m/CD3-zmRNA (NOD with ins;
shown in filled black bars) or IGRP/b2m/CD3-zmRNA (NOD with IGRP; shown in filled gray bars) were co-incubated for 24 hr with PKH26-labeled target InsB15–23-reactive
G9 or IGRP206–214-reactive NY8.3 CD8 T cells, respectively, at effector-to-target (E:T) ratios of 1:1 or 5:1, in duplicate. As controls, the same target cells were incubated with
cells electroporated in the absence of mRNA (NOD no RNA), as shown in light hatched bars or dark hatched bars, respectively. TO-PRO-3 was added to the cells and the
percentage of lysed cells was determined by flow cytometric analysis. Controls showing target G9 T cells or NY8.3 T cells are shown in the open bars. The graph shown is
representative of nine similar experiments. The error bars represent SD of the mean.
Molecular Therapyby autoreactive CD8 T cells. The autoreactive CD8 T cells are selec-
tively removed, as illustrated by the in vitro assays. We have also
shown that peptide/b2m/CD3-z can target speciﬁc autoreactive
CD8 T cells in vivo and reduce the incidence of autoimmune diabetes.
The simultaneous immunotargeting of a number of dominant autor-
eactive CD8 T cell clones by the peptide/b2m/CD3-z constructs can
be attained either by the co-transfection of the same polyclonal
CD8 T cells with a combination of mRNAs encoding the respective
peptide/b2m/CD3-z polypeptides or the co-administration of a
mixture of T cell transfectants, each of which expresses a different
peptide/b2m/CD3-z mRNA. In the current study, we have demon-
strated the functional expression of the different mRNA species,
each co-transfected (when needed) with mRNA encoding the
H-2Kd heavy chain (Figure 2A). In this experiment, the activation
of transfectants by MHC-I cross-linking required the functional
expression and pairing of the polypeptide products of both mRNA
encoding MHC-I as well as the peptide/b2m/CD3-z. Nevertheless,
it was almost as powerful as cellular activation triggered by TCR
cross-linking under exactly the same conditions. In an accompanying
study,42 we recently showed that mRNA encoding peptide/MHC-II/
CD3-z can be similarly used to efﬁciently redirect T cells against path-
ogenic CD4 T cells in a peptide-speciﬁc manner. Likewise, in that
study, T cell activation through the chimeric MHC-II molecules,
which also required co-expression and pairing of the two products,
was comparable to TCR-mediated activation. The current achieve-
ment complements our arsenal of genetic immunotargeting devices
against both CD4 and CD8 islet-reactive T cells in the NOD mouse.
The demonstration that redirected polyclonal NOD CD8 T cells kill
autoreactive CD8 T cells (Figure 3) recapitulates our previous ﬁnd-
ings31 in which the insulin-reactive CD8 T cells were killed by pre-
activated T cells that expressed InsB15–23/b2m/CD3-z as a transgene.460 Molecular Therapy Vol. 25 No 2 February 2017However, while those transgenic experiments illustrated the principle
that CD8 T cells could be effectively redirected to kill antigen-speciﬁc
targets, this procedure would not be translatable for immunotherapy
in humans. In the current study, the strategy brings the procedure a
step nearer to translation, in that we have shown that primary cells
can be readily transfected with the mRNA construct and can kill in-
sulin-reactive targets in a similar manner.
When the InsB15–23/b2m/CD3-z or IGRP206–214/b2m/CD3-zmRNA-
transfected cells were transferred to young NOD female mice, protec-
tion from diabetes was only seen when the cells targeted InsB15–23-
reactive T cells. The injection was done at a time (5–6 weeks of
age) when insulin-reactive cells are detected in the pancreatic lymph
nodes in a higher proportion than at later time points. In contrast,
IGRP-reactive T cells tend to rise later on, so that injecting the cells
at this young age may be more likely to target insulin-reactive
T cells.10,19 In principle, cell transfer aiming at immunotargeting
T cells of both autoreactivities can be carried out at different time
points, so that the earlier transfer targets insulin-reactive T cells
and the later one targets IGRP-reactive cells. The current study dem-
onstrates proof of principle and further studies will be carried out in
the future to optimize timing of injections, including injections at
later time points and whether more than one adoptive cell transfer
may be required.
To our knowledge, this work is the ﬁrst demonstration that mRNA-
transfected T cells expressing chimeric MHC complexes can selec-
tively immunotarget pathogenic T cells in vivo and inhibit or reduce
the incidence of autoimmune diabetes. We are also evaluating the
similar reprogramming of regulatory T cells in an ongoing study, hy-
pothesizing that the targeting of a narrow population of autoreactive
CD8 or CD4 T cell clones may sufﬁce for eliciting a broad tolerizing
effect.
Figure 4. Insulitis and Diabetes in NOD Mice
following Transfer of mRNA-Transfected Cells
Female NOD mice were transferred with 107 NOD CD8
T cells that had been transfected with InsB15–23/b2m/
CD3-z mRNA (Ins; n = 16), IGRP206–214/b2m/CD3-z
mRNA (IGRP; n = 16), or control cells electroporated but
without mRNA (Mock; n = 24). The mice were screened
weekly for glycosuria and following two consecutive
positive readings, diabetes was confirmed by a blood
glucose reading of >13.9 mmol/L. (A) Incidence of dia-
betes is shown with data that were analyzed by log-rank
survival statistics, comparing the Ins group with the Mock
group (p = 0.031). (B) Insulitis scores either when the mice
developed diabetes or for the non-diabetic mice at
35 weeks of age are shown. We examined 80–115 islets
from at least three mice in each group. The sections were
stained with anti-CD8 (top), anti-CD4 (middle), and anti-
B220 for B cells (bottom). Scoring for insulitis was as
follows: 0, no insulitis; 1, peri-insulitis; 2, less than 50%
infiltration; and 3, more than 50% infiltration. Data were
analyzed by the c2 test. (C) Examples of the insulitis are
shown, with separate staining for CD8 and CD4 T cells, B
cells (B220), and insulin, all stained in red, in a diabetic
mouse and a non-diabetic mouse. Magnification is 100.
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DNA Vectors and Plasmids
The pGEMT vector for direct cloning of PCR products was from
Promega. Template DNA for in vitro transcription of mRNA was
cloned into the pGEM4Z/GFP/A64 vector,43 a kind gift from Dr. E.
Gilboa (University of Miami) following the removal of the GFP insert
(pGEM4Z/A64).
Assembly of Genetic Constructs
All PCR products were sub-cloned and their DNA sequence was
conﬁrmed prior to insertion in expression vectors. For cloning of
the four constructs encoding peptide/human b2m/mouse CD3-z,
we used essentially the same cloning strategy we described previ-
ously.9 The gene segment encoding the full leader sequence of humanMob2m, the antigenic peptide, and the N-terminal
part of the linker was ampliﬁed from a hb2m
cDNA clone (prepared from Jurkat cells) with
the forward primer 50-GGG TCT AGA GCC
GAG ATG TCT CGC TCC GTG-30 and one
of the following reverse primers: 50-CGC GGA
TCC GCC ACC TCC CAC ACG CTC CCC
ACA CAC CAG GTA GAG AGC CTC AAG
GCC AGA AAG-30 for the InsB15–23 variant
peptide G9V (LYLVCGERV44), 50-CGC GGA
TCC GCC ACC TCC AAG AAA AAC ATT
AGT TTT AAG ATA AAC AGC ATA CAA
GCC GGT CAG-30 for IGRP206–214
(VYLKTNVFL), 50-CGC GGA TCC GCC
ACC TCC AAC TTT ATC ACC AAG AGG
TTG ATA AGA AGC ATA CAA GCC GGTCAG-30 for GAD65546–554 (SYQPLGDKV), and 5-CGC GGA TCC
GCC ACC TCC AAG ATA AAG ATA ATT TTC ATC TTG AAA
AGCATA CAAGCCGGTCAG-30 for DMK138–146 (FQDENYLYL).
The resulting XbaI/BamHI fragment and a BamHI/EcoRI fragment
encoding the hb2m/CD3-z portion of the chimeric polypeptide
9
were inserted into pGEM4Z/A64.
Cell Lines
B3Z45 is an ovalbumin (OVA)257–264-speciﬁc, H-2K
b-restricted CTL
hybridoma and was a kind gift from Dr. N. Shastri (University of
California, Berkeley). CHIB2 is an InsB15–23-speciﬁc hybrid of the
G9C8 T cell clone with the BW5147 thymoma expressing CD8,
H-2Kd-restricted T cell hybridoma.10 Both B3Z and CHIB2 harbor
the nuclear factor of activated T cells-lacZ inducible reporter gene.46lecular Therapy Vol. 25 No 2 February 2017 461
Molecular TherapyIn Vitro Transcription and Electroporation of mRNA
Template DNA cloned in pGEM4Z/A64 was prepared with the Endo-
Free Plasmid Maxi Kit (Promega) and linearized using the SpeI re-
striction site positioned at the 30 end of the poly(A) tract of the vector.
In vitro transcription was conducted in a 20-mL reaction mix at 37C
using the T7 mScript Standard mRNA Production System (Cell-
Script) to generate 50-capped in vitro-transcribed mRNA. Cells
were washed twice with OptiMEM medium (Gibco) and re-sus-
pended in 200 mL OptiMEM containing the required amount of
in vitro-transcribed mRNA (10–20 mg in most experiments). Electro-
poration was performed with Gene Pulser Xcell (Bio-Rad Labora-
tories) in 2-mm cuvettes using a square wave pulse (1 millisecond,
300 V) for the experiments with cell lines, or with BTX Harvard
Apparatus ECM830 (1 millisecond, 300 V) for the primary cells.
Mice
NOD mice, originally from the NOD/CaJ colony at Yale University,
and G9 TCR transgenic mice47 have been bred at Cardiff University
for 5 years. NY8.3 TCR transgenic mice48 were purchased from Jack-
son Laboratory. These mice were housed in microisolators at the spe-
ciﬁc pathogen-free facility at Cardiff University. BALB/c mice were
maintained at the animal facility of the Bar-Ilan University Faculty
of Medicine. All procedures were performed in accordance with pro-
tocols approved by the UK Home Ofﬁce and the Israeli National
Committee Institutional Animal Care and Use Committee.
Antibodies and Reagents
Anti-H-2Kd monoclonal antibody (mAb) (clone SF1-1.1) was from
Pharmingen and anti-H-2Db mAb was puriﬁed from the supernatant
of the 28-14-8 hybridoma. 2C11 is a hamster mAb speciﬁc to mouse
CD3ε. mAb against hb2m (clone BM-63) was from Sigma. Rabbit
polyclonal antibodies against hb2m were from Dako. Hamster mAb
to mouse CD3z (clone H146-968) was from Santa Cruz Biotech-
nology. Horseradish peroxidase (HRP)-conjugated goat antibodies
against rabbit IgG were from Jackson Laboratory. Rabbit antibodies
against hamster IgG and ﬂuorescein isothiocyanate (FITC)-conju-
gated goat anti-mouse IgG and FITC-conjugated donkey anti-mouse
IgG were from Sigma and Jackson Laboratory, respectively. HRP-
conjugated rabbit antibodies against hamster IgG were from Sigma.
Biotinylated rat anti-mouse CD4 (clone GK1.5) was purchased
from Biolegend. Biotinylated rat anti-mouse CD8a (clone 53-6.7)
and rat anti-mouse B220 (clone RA3-6B2) were from BDPharmingen
and biotinylated mouse anti-insulin antibody (ICBTACLS) was from
eBioscience.
Flow Cytometry
One million cultured cells or primary cells harvested from the spleen
of mice were used. Single cell suspensions were either stained with the
respective monoclonal antibodies in a direct staining procedure or,
for indirect staining, the cells were incubated with the primary anti-
body for 1 hr and then washed before further incubation with ﬂuoro-
phore-labeled secondary antibody at 4C. Cells were washed twice, re-
suspended in 1 mL cold PBS, and analyzed by a FACSCalibur or
FACSCanto system (Becton Dickinson). Data were analyzed by462 Molecular Therapy Vol. 25 No 2 February 2017FCS Express (version 4; De Novo Software) or FlowJo (version
7.6.5; Tree Star) software.
Chlorophenol Red b-D-Galactopyranoside Assay
B3Z transfected cells were incubated in plates coated with immobi-
lized MHC-I antibody or with CHIB2 hybridoma cells overnight.
The culture medium was removed and 100 mL lysis buffer (9 mM
MgCl2, 0.125% NP-40, and 0.3 mM chlorophenol red b-D-galacto-
pyranoside [CPRG] in PBS) was added to each well. One to 24 hr
post-lysis, the optical density (OD) of each well was measured using
an ELISA reader (at 570 nm, with 630 nm as reference).
Immunoblot Analysis
Protein samples were boiled for 3 minutes, separated on a 10% non-
reducing SDS polyacrylamide gel at 50 mA, and transferred onto a
nitrocellulose membrane. The membrane was blocked with milk
buffer (0.3 g Na2HPO4, 2.19 g NaCl, 25 mL water, and 225 mL 1%
low-fat milk) overnight at 4C and 1 hr at room temperature, washed
twice with PBS, and incubated for 2 hr with the primary antibody. The
membrane was then washed six times for 6 min with PBS, incubated
for 1 hr with the secondary peroxidase-conjugated antibody, washed
six times for 6 min with TPBS (PBS with 0.05% Tween 20), washed six
times for 6 min with PBS, and then developed using an ECL
(enhanced chemiluminescence) kit (Pierce-Thermo Fisher Scientiﬁc)
and X-ray ﬁlm 100NIF (Fuji).
Cytotoxicity Assay
CD8 T cells were isolated from the spleen of 5- to 6-week-old NOD
mice and separated by negative selection (MACS; Miltenyi Biotec).
The puriﬁed CD8 T cells were then activated and expanded by stim-
ulation using plate-bound anti-CD3 and anti-CD28 antibodies, inter-
leukin (IL)-2 and IL-7 as previously described.49 The activated CD8
T cells were transfected with mRNA encoding InsB15–23/b2m/CD3-
z or IGRP206–214/b2m/CD3-z. These cells were the effector cells of
the assay. G9 and NY8.3 TCR transgenic CD8+ T cells were puriﬁed
by negative selection (MACS; Miltenyi Biotec) from the spleens of G9
and NY8.3 transgenic mice, respectively. Activated mRNA-trans-
fected T cells (effectors) were incubated with puriﬁed G9 or NY8.3
T cells (targets), labeled with PKH-26 (Sigma), at an effector-to-target
ratio of 1:1 and 5:1 for 16 hr at 37C. To detect cell death, TO-PRO-3
iodide (Thermo Fisher Scientiﬁc) was added immediately prior to
ﬂow cytometric analysis. Single PKH-26+TO-PRO-3+ cells were
gated, and cytotoxicity was expressed as the percentage of dead
cells/total targets.31 Activated CD8 T cells with no transfected
mRNA served as controls for the effector T cells.
Adoptive Transfer
NOD CD8 T cells were isolated, activated, expanded, and transfected
with mRNA as described for the cytotoxicity assay. As a control,
CD8+ T cells were subjected to the electroporation procedure but
with no added mRNA (mock transfection). Transfected cells (pep-
tide/b2m/CD3-z construct and mock-transfected) were adoptively
transferred into 6-week-old NOD mice recipients by injection into
the tail vein (6–10  106 cells per mouse).
www.moleculartherapy.orgDiagnosis of Diabetes
Mice were screened weekly for glycosuria (Diastix; Bayer) and,
following two consecutive positive readings, diabetes was conﬁrmed
by a blood glucose reading of >13.9 mmol/L.
Histology
The pancreas was ﬁxed in paraformaldehyde lysine periodate buffer
overnight and then infused with 10% sucrose followed by 20% su-
crose, as previously described.31 The pancreas was then embedded
in OCT and snap frozen for immunohistochemistry. Frozen sections
of 10-mm thickness were cut and stained with rat anti-mouse CD4,
CD8, B220, and anti-insulin antibodies and detected with streptavi-
din-alkaline phosphatase and a Vector Red AP substrate kit (Vector
Laboratories). The sections were counter-stained with hematoxylin.
Insulitis was assessed from at least three mice per group and
80–115 islets were scored. Scoring for insulitis is shown in the legend
for Figure 4.
Statistical Analysis
Log-rank analysis was carried out for the adoptive transfer experi-
ments. The c2 test was performed for the analysis of insulitis. For
all tests, p < 0.05 was considered statistically signiﬁcant.
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